BACKGROUND: Buprenorphine is a key tool in the management of opioid use disorder, but there are growing concerns about abuse, diversion, and safety. These concerns are amplified for the Department of Veterans Affairs (VA), whose patients may receive care concurrently from multiple prescribers within and outside VA. To illustrate the extent of this challenge, we examined overlapping prescriptions for buprenorphine, opioids, and benzodiazepines among veterans dually enrolled in VA and Medicare Part D. METHODS: We constructed a cohort of all veterans dually enrolled in VA and Part D who filled an opioid prescription in 2012. We identified patients who received tablet or film buprenorphine products from either source. We calculated the proportion of buprenorphine recipients with any overlapping prescription (based on days supply) for a nonbuprenorphine opioid or benzodiazepine, focusing on veterans who received overlapping prescriptions from a different system than their buprenorphine prescription (Part D buprenorphine recipients receiving overlapping opioids or benzodiazepines from VA and vice versa). RESULTS: There were 1790 dually enrolled veterans with buprenorphine prescriptions, including 760 (43%) from VA and 1091 (61%) from Part D (61 veterans with buprenorphine from both systems were included in each group). Among VA buprenorphine recipients, 199 (26%) received an overlapping opioid prescription and 11 (1%) received an overlapping benzodiazepine prescription from Part D. Among Part D buprenorphine recipients, 208 (19%) received an overlapping opioid prescription and 178 (16%) received an overlapping benzodiazepine prescription from VA. Among VA and Part D buprenorphine recipients with cross-system opioid overlap, 25% (49/199) and 35% (72/208), respectively, had >90 days of overlap. CONCLUSIONS: Many buprenorphine recipients receive overlapping prescriptions for opioids and benzodiazepines from a different health care system than the one in which their buprenorphine was filled. These findings highlight a previously undocumented safety risk for veterans dually enrolled in VA and Medicare.
BACKGROUND:Buprenorphine is a key tool in the management of opioid use disorder, but there are growing concerns about abuse, diversion, and safety. These concerns are amplified for the Department of Veterans Affairs (VA), whose patients may receive care concurrently from multiple prescribers within and outside VA. To illustrate the extent of this challenge, we examined overlapping prescriptions for buprenorphine, opioids, and benzodiazepines among veterans dually enrolled in VA and Medicare Part D. METHODS: We constructed a cohort of all veterans dually enrolled in VA and Part D who filled an opioid prescription in 2012. We identified patients who received tablet or film buprenorphine products from either source. We calculated the proportion of buprenorphine recipients with any overlapping prescription (based on days supply) for a nonbuprenorphine opioid or benzodiazepine, focusing on veterans who received overlapping prescriptions from a different system than their buprenorphine prescription (Part D buprenorphine recipients receiving overlapping opioids or benzodiazepines from VA and vice versa). RESULTS: There were 1790 dually enrolled veterans with buprenorphine prescriptions, including 760 (43%) from VA and 1091 (61%) from Part D (61 veterans with buprenorphine from both systems were included in each group). Among VA buprenorphine recipients, 199 (26%) received an overlapping opioid prescription and 11 (1%) received an overlapping benzodiazepine prescription from Part D. Among Part D buprenorphine recipients, 208 (19%) received an overlapping opioid prescription and 178 (16%) received an overlapping benzodiazepine prescription from VA. Among VA and Part D buprenorphine recipients with cross-system opioid overlap, 25% (49/199) and 35% (72/208), respectively, had >90 days of overlap. CONCLUSIONS: Many buprenorphine recipients receive overlapping prescriptions for opioids and benzodiazepines from a different health care system than the one in which their buprenorphine was filled. These findings highlight a previously undocumented safety risk for veterans dually enrolled in VA and Medicare.
Authors: Zev Schuman-Olivier; Bettina B Hoeppner; Roger D Weiss; Jacob Borodovsky; Howard J Shaffer; Mark J Albanese Journal: Drug Alcohol Depend Date: 2013-05-18 Impact factor: 4.492
Authors: Adam J Rose; Dana Bernson; Kenneth Kwan Ho Chui; Thomas Land; Alexander Y Walley; Marc R LaRochelle; Bradley D Stein; Thomas J Stopka Journal: J Gen Intern Med Date: 2018-06-14 Impact factor: 5.128
Authors: Devon K Check; Aaron N Winn; Nicole Fergestrom; Katherine E Reeder-Hayes; Joan M Neuner; Andrew W Roberts Journal: J Natl Cancer Inst Date: 2020-12-14 Impact factor: 13.506
Authors: Thomas R Radomski; Felicia R Bixler; Susan L Zickmund; KatieLynn M Roman; Carolyn T Thorpe; Jennifer A Hale; Florentina E Sileanu; Leslie R M Hausmann; Joshua M Thorpe; Katie J Suda; Kevin T Stroupe; Adam J Gordon; Chester B Good; Michael J Fine; Walid F Gellad Journal: J Gen Intern Med Date: 2018-03-08 Impact factor: 5.128
Authors: Pooja A Lagisetty; Lewei A Lin; Dara Ganoczy; Rebecca L Haffajee; Theodore J Iwashyna; Amy S B Bohnert Journal: Med Care Date: 2019-10 Impact factor: 2.983
Authors: Winn Cashion; Walid F Gellad; Florentina E Sileanu; Maria K Mor; Michael J Fine; Jennifer Hale; Daniel E Hall; Shari Rogal; Galen Switzer; Mohan Ramkumar; Virginia Wang; Douglas A Bronson; Mark Wilson; William Gunnar; Steven D Weisbord Journal: Clin J Am Soc Nephrol Date: 2021-02-18 Impact factor: 8.237
Authors: Geetanjoli Banerjee; E Jennifer Edelman; Declan T Barry; Stephen Crystal; Kirsha S Gordon; Adam J Gordon; Julie R Gaither; Traci C Green; Robert D Kerns; Ajay Manhapra; Brent A Moore; David A Fiellin; Brandon D L Marshall Journal: Pain Date: 2019-09 Impact factor: 7.926
Authors: Carolyn T Thorpe; Walid F Gellad; Maria K Mor; John P Cashy; John R Pleis; Courtney H Van Houtven; Loren J Schleiden; Joseph T Hanlon; Joshua D Niznik; Ronald L Carico; Chester B Good; Joshua M Thorpe Journal: Health Serv Res Date: 2018-10-16 Impact factor: 3.734
Authors: Lindsay B Miller; Heidi Sjoberg; Ashlea Mayberry; Marina S McCreight; Roman A Ayele; Catherine Battaglia Journal: BMC Health Serv Res Date: 2019-10-22 Impact factor: 2.655
Authors: R Neal Axon; Mulugeta Gebregziabher; Charles J Everett; Paul Heidenreich; Kelly J Hunt Journal: J Am Heart Assoc Date: 2018-08-07 Impact factor: 5.501